Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study

Octreotide long-acting repeatable (LAR) is largely used to treat functional and/or metastatic neuroendocrine neoplasms (NENs). Its effect in controlling carcinoid syndrome and partially reduce tumour burden is attributable to the ability of octreotide to bind somatostatin receptors (SSTRs) on the tu...

Descripción completa

Detalles Bibliográficos
Autores principales: von Arx, Claudia, Rea, Giuseppina, Napolitano, Maria, Ottaiano, Alessandro, Tatangelo, Fabiana, Izzo, Francesco, Petrillo, Antonella, Clemente, Ottavia, Di Sarno, Antonella, Botti, Gerardo, Scala, Stefania, Tafuto, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563951/
https://www.ncbi.nlm.nih.gov/pubmed/32859050
http://dx.doi.org/10.3390/cancers12092422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563951/
https://www.ncbi.nlm.nih.gov/pubmed/32859050
http://dx.doi.org/10.3390/cancers12092422

Ejemplares similares